CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
SenolT is a diagnostic test designed to detect senescent cells associated with cancer recurrence, particularly in pancreatic and triple negative breast cancers. By identifying these cells early, the test aims to improve patient outcomes following chemotherapy and radiotherapy, targeting pharmaceutical companies for mar…
The main concern in cancer treatment is its high rate of recurrence.
It may happen soon or years after treatment and it’s very hard to predict/prevent.
Removing residual tumour cells is the best way to avoid recurrence, so identifying new tumour markers is the most pressing demand.
We have developed SenolT, an innovative diagnostic test for the early detection and monitoring of senescent cells, which appear after chemotherapy/radiotherapy and are directly associated to cancer recurrence.
SenolT…
SENOLYTIC THERAPEUTICS SL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
